Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, benign prostatic hyperplasia (BPH), Kennedy's disease, androgenetic alopecia, breast cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy.
1. A method of treating cancer comprising administering an effective amount of a compound selected from the group consisting of
3β-(1H-imidazol-1-yl)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP433-3β (A1)),
3β-(pyridine-4-ylmethoxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP414(A16)),
6-(3-benzimidazolylphenyl)naphthalen-2-ol (VNPP372/2(Na1)), and
N-(3-benzimidazolylphenyl)[(4-methoxyphenyl) sulphonyl]amine (VNPP431(SulAmd2))
to a patient in need thereof,
wherein said cancer is prostate cancer or castration resistant human prostate cancer.
2. The method of claim 1 , wherein said cancer is prostate cancer.
3. The method of claim 1 , wherein said cancer is castration resistant human prostate cancer.
4. A method of degrading a full length androgen receptor or a splice variant androgen receptor, the method comprising administering an effective amount of a compound selected from the group consisting of
3β-(1H-imidazol-1-yl)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP433-3β (A1)),
3β-(pyridin-4-ylmethoxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP414(A16),
6-(3-benzimidazolylphenyl)naphthalen-2-ol (VNPP372/2(Na1)), and
N-(3-benzimidazolylphenyl)[(4-methoxyphenyl) sulphonyl]amine (VNPP431(SulAmd2))
to a patient in need thereof.
5. A method of inhibiting proliferation of androgen sensitive cell line comprising administering an effective amount of a compound selected from the group consisting of
3 β-(1H-imidazol-1-yl)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP433-3β (Al)),
3β-(pyridin-4-ylmethoxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP414(A16),
6-(3-benzimidazolylphenyl)naphthalen-2-ol (VNPP372/2 (Na1)), and
N-(3-benzimidazolylphenyl)[(4-methoxyphenyl) sulphonyl]amine (VNPP431(SulAmd2))
to a patient in need thereof.
6. A method of treating cancer, comprising administering an effective amount of a compound selected from the group consisting of 3β-(1H-imidazol-1-yl)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP433-3β (A1)), and 3β-(pyridin-4-ylmethoxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP414 (A16)) to a patient in need thereof,
wherein the cancer is at least one selected from the group consisting of prostate cancer and castration resistant prostate cancer.
7. The method of treating cancer according to claim 6 , wherein the compound is 3,β-(1H-imidazol-1-yl)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP433-3β (A1)).
8. The method of treating cancer according to claim 6 , wherein the compound is 3β-(pyridin-4-ylmethoxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (VNPP414 (A16)).
9. The method of treating cancer according to claim 6 , wherein the cancer is prostate cancer.
10. The method of treating cancer according to claim 6 , wherein the cancer is castration resistant prostate cancer.